
|Videos|February 23, 2023
Selecting an Appropriate BCMA-Directed Bispecific for Patients with R/R MM
The panel describes the factors they consider when selecting an appropriate BCMA-directed bispecific antibody for a patient with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
2
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
3
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
4
Neoadjuvant Systemic Therapy Explored in Head and Neck Cancer Trial
5




















